great play for the coming weeks
Outlook 2007:
Evamist (1,5 B$ Market) FDA approval in Juli 2007
Testosterone MD-Lotion Phase 2 results in Juli
Testosterone MDTS start Phase 3 Mid-2007
http://www.acrux.com.au/IRM/Company/ShowPage.aspx?CPID=1193
In our view, these elements, combined with ACR’s extensive pipeline of
product, provide one of the best investment opportunities in the sector. We
expect our price target of $1.90 will be achieved within the next 12-months
and could easily be exceeded if ACR continues to stand and deliver good
commercial outcomes.
- Forums
- ASX - By Stock
- acr vs mbp
great play for the coming weeksOutlook 2007:Evamist (1,5 B$...
Featured News
Add MBP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online